BioCentury | Apr 2, 2009
Company News

Orexigen names Narachi CEO

...president and CEO of Ren Pharmaceuticals Inc. (South San Francisco, Calif.) and executive chairman of Naryx Pharma Inc....
BioCentury | Dec 3, 2007
Clinical News

Sybryx: Completed Phase IIb enrollment

...with chronic sinusitis in a double-blind, U.S. Phase IIb trial (SPRC-AB01-003) comparing Sybryx vs. placebo. Naryx Pharma Inc....
BioCentury | Jul 2, 2007
Company News

Naryx management update

Naryx Pharma Inc. , Carpinteria, Calif. Business: Infectious Hired: Andy Strayer as VP of clinical operations and medical affairs, formerly SVP of clinical operations for the Americas and Asia at Pharmaceutical Product Development Inc. WIR Staff...
BioCentury | Apr 23, 2007
Clinical News

SPRC-AB01 regulatory update

...sinusitis in post-surgical patients. The intranasal antibiotic is in Phase IIb testing for the indication. Naryx Pharma Inc....
BioCentury | Nov 13, 2006
Company News

Advanced Magnetics board of directors update

...Ron Zwanziger, chairman and CEO of Inverness Medical Innovations Inc.; and Michael Narachi, chairman of Naryx Pharma Inc. WIR...
BioCentury | Nov 13, 2006
Company News

Naryx board of directors update

Naryx Pharma Inc. , Carpinteria, Calif. Business: Infectious Appointed: Alan Colowick, president of oncology at Geron Corp. WIR Staff Infectious...
BioCentury | Jun 20, 2005
Clinical News

SPRC-AB01: Phase II data

...from the trial, but the endpoint was a composite of 3 separate signs and symptoms. Naryx...
...discuss the trial and that it plans to start additional, undisclosed trials later this year. Naryx Pharma Inc....
BioCentury | May 23, 2005
Company News

Naryx board of directors update

Naryx Pharma Inc. , Carpinteria, Calif. Business: Infectious Appointed: Alan Forsythe, retired VP of corporate biomedical information at Amgen Inc. WIR Staff...
BioCentury | Dec 20, 2004
Clinical News

SPRC-AB01: Started Phase II

...about 60 CRS patients who have had sinus surgery, but continue to have bacterial infections. SinusPharma...
BioCentury | Dec 15, 2004
Clinical News

SinusPharma starts sinusitis Phase II

SinusPharma (Carpinteria, Calif.) began a double-blind, placebo-controlled, U.S. Phase II trial of its SPRC-AB01 antibiotic for nasal inhalation to treat chronic rhinosinusitis. The primary endpoint of the trial is reduction in total signs and symptoms...
Items per page:
1 - 10 of 12
BioCentury | Apr 2, 2009
Company News

Orexigen names Narachi CEO

...president and CEO of Ren Pharmaceuticals Inc. (South San Francisco, Calif.) and executive chairman of Naryx Pharma Inc....
BioCentury | Dec 3, 2007
Clinical News

Sybryx: Completed Phase IIb enrollment

...with chronic sinusitis in a double-blind, U.S. Phase IIb trial (SPRC-AB01-003) comparing Sybryx vs. placebo. Naryx Pharma Inc....
BioCentury | Jul 2, 2007
Company News

Naryx management update

Naryx Pharma Inc. , Carpinteria, Calif. Business: Infectious Hired: Andy Strayer as VP of clinical operations and medical affairs, formerly SVP of clinical operations for the Americas and Asia at Pharmaceutical Product Development Inc. WIR Staff...
BioCentury | Apr 23, 2007
Clinical News

SPRC-AB01 regulatory update

...sinusitis in post-surgical patients. The intranasal antibiotic is in Phase IIb testing for the indication. Naryx Pharma Inc....
BioCentury | Nov 13, 2006
Company News

Advanced Magnetics board of directors update

...Ron Zwanziger, chairman and CEO of Inverness Medical Innovations Inc.; and Michael Narachi, chairman of Naryx Pharma Inc. WIR...
BioCentury | Nov 13, 2006
Company News

Naryx board of directors update

Naryx Pharma Inc. , Carpinteria, Calif. Business: Infectious Appointed: Alan Colowick, president of oncology at Geron Corp. WIR Staff Infectious...
BioCentury | Jun 20, 2005
Clinical News

SPRC-AB01: Phase II data

...from the trial, but the endpoint was a composite of 3 separate signs and symptoms. Naryx...
...discuss the trial and that it plans to start additional, undisclosed trials later this year. Naryx Pharma Inc....
BioCentury | May 23, 2005
Company News

Naryx board of directors update

Naryx Pharma Inc. , Carpinteria, Calif. Business: Infectious Appointed: Alan Forsythe, retired VP of corporate biomedical information at Amgen Inc. WIR Staff...
BioCentury | Dec 20, 2004
Clinical News

SPRC-AB01: Started Phase II

...about 60 CRS patients who have had sinus surgery, but continue to have bacterial infections. SinusPharma...
BioCentury | Dec 15, 2004
Clinical News

SinusPharma starts sinusitis Phase II

SinusPharma (Carpinteria, Calif.) began a double-blind, placebo-controlled, U.S. Phase II trial of its SPRC-AB01 antibiotic for nasal inhalation to treat chronic rhinosinusitis. The primary endpoint of the trial is reduction in total signs and symptoms...
Items per page:
1 - 10 of 12